{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:21:16Z","timestamp":1778278876408,"version":"3.51.4"},"reference-count":137,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic venous disease (CVD) is a common pathology, with significant physical and psychological impacts for patients and high economic costs for national healthcare systems. Throughout the last decades, several risk factors for this condition have been identified, but only recently, have the roles of inflammation and endothelial dysfunction been properly assessed. Although still incompletely understood, current knowledge of the pathophysiological mechanisms of CVD reveals several potential targets and strategies for therapeutic intervention, some of which are addressable by currently available venoactive drugs. The roles of these drugs in the clinical improvement of venous tone and contractility, reduction of edema and inflammation, as well as in improved microcirculation and venous ulcer healing have been studied extensively, with favorable results reported in the literature. Here, we aim to review these pathophysiological mechanisms and their implications regarding currently available venoactive drug therapies.<\/jats:p>","DOI":"10.3390\/ijms19061669","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T06:25:52Z","timestamp":1528179952000},"page":"1669","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":203,"title":["Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy"],"prefix":"10.3390","volume":"19","author":[{"given":"Armando","family":"Mansilha","sequence":"first","affiliation":[{"name":"Departamento de Cirurgia e Fisiologia, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"Departamento de Angiologia e Cirurgia Vascular, Hospital CUF Porto, 4100-180 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-7702","authenticated-orcid":false,"given":"Joel","family":"Sousa","sequence":"additional","affiliation":[{"name":"Departamento de Cirurgia e Fisiologia, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal"},{"name":"Departamento de Angiologia e Cirurgia Vascular, Hospital CUF Porto, 4100-180 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMra055289","article-title":"Chronic venous disease","volume":"355","author":"Bergan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/CIRCULATIONAHA.113.006898","article-title":"Chronic venous insufficiency","volume":"130","author":"Eberhardt","year":"2014","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jvs.2004.09.027","article-title":"Revision of the CEAP classification for chronic venous disorders: Consensus statement","volume":"40","author":"Eklof","year":"2004","journal-title":"J. Vasc. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.annepidem.2004.05.015","article-title":"The epidemiology of chronic venous insufficiency and varicose veins","volume":"15","author":"Pfeifer","year":"2005","journal-title":"Ann. Epidemiol."},{"key":"ref_5","first-page":"105","article-title":"Epidemiology of chronic venous disorders in geographically diverse populations: Results from the Vein Consult Program","volume":"31","author":"Rabe","year":"2012","journal-title":"Int. Angiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jvs.2004.07.025","article-title":"Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: A population-based study in France","volume":"40","author":"Carpentier","year":"2004","journal-title":"J. Vasc. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ejvs.2015.05.013","article-title":"Association of Venous Disorders with Leg Symptoms: Results from the Bonn Vein Study 1","volume":"50","author":"Wrona","year":"2015","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/jech.53.3.149","article-title":"Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study","volume":"53","author":"Evans","year":"1999","journal-title":"J. Epidemiol. Commun. Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jvsv.2012.05.006","article-title":"Incidence of chronic venous disease in the Edinburgh Vein Study","volume":"1","author":"Robertson","year":"2013","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1177\/0003319701052001S02","article-title":"Prevalence and risk factors of chronic venous insufficiency","volume":"52","author":"Fowkes","year":"2001","journal-title":"Angiology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1177\/0003319703054001S04","article-title":"The influence of environmental factors in chronic venous insufficiency","volume":"54","author":"Jawien","year":"2003","journal-title":"Angiology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1067\/mva.2002.126547","article-title":"Chronic venous insufficiency: Clinical and duplex correlations. The Edinburgh Vein Study of venous disorders in the general population","volume":"36","author":"Ruckley","year":"2002","journal-title":"J. Vasc. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/ije\/30.4.846","article-title":"Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Study","volume":"30","author":"Fowkes","year":"2001","journal-title":"Int. J. Epidemiol."},{"key":"ref_14","first-page":"172","article-title":"Epidemiology of venous insufficiency in an occupational population","volume":"22","author":"Lacroix","year":"2003","journal-title":"Int. Angiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1258\/phleb.2007.007061","article-title":"Epidemiology of chronic venous disease","volume":"23","author":"Robertson","year":"2008","journal-title":"Phlebology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0749-3797(18)31203-0","article-title":"The epidemiology of varicose veins: The Framingham Study","volume":"4","author":"Brand","year":"1988","journal-title":"Am. J. Prevent. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1258\/phleb.2012.012s23","article-title":"The relevance of the natural history of varicose veins and refunded care","volume":"27","author":"Pannier","year":"2012","journal-title":"Phlebology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jvsv.2014.09.008","article-title":"Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study","volume":"3","author":"Lee","year":"2015","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jvs.2003.12.007","article-title":"Relationship between clinical classification of chronic venous disease and patient-reported quality of life: Results from an international cohort study","volume":"39","author":"Kahn","year":"2004","journal-title":"J. Vasc. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-0037-1613595","article-title":"Quality of life in venous disease","volume":"90","author":"Vossen","year":"2003","journal-title":"Thromb. Haemost."},{"key":"ref_21","first-page":"185","article-title":"[Venous disease in France: An unrecognized public health problem]","volume":"19","author":"Lafuma","year":"1994","journal-title":"J. Mal. Vasc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0002-9610(01)00856-X","article-title":"Validation of venous leg ulcer guidelines in the United States and United Kingdom","volume":"183","author":"McGuckin","year":"2002","journal-title":"Am. J. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s11136-011-0008-3","article-title":"Construction and international validation of CIVIQ-14 (a short form of CIVIQ-20), a new questionnaire with a stable factorial structure","volume":"21","author":"Launois","year":"2012","journal-title":"Qual. Life Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ejvs.2010.03.034","article-title":"International psychometric validation of the Chronic Venous Disease quality of life Questionnaire (CIVIQ-20)","volume":"40","author":"Launois","year":"2010","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/0268355513479582","article-title":"Linguistic validation of the 20 item-chronic venous disease quality-of-life questionnaire (CIVIQ-20)","volume":"29","author":"Launois","year":"2014","journal-title":"Phlebology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jvsv.2014.08.005","article-title":"Health-related quality-of-life scales specific for chronic venous disorders of the lower limbs","volume":"3","author":"Launois","year":"2015","journal-title":"J Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref_27","first-page":"439","article-title":"The importance of chronic venous insufficiency. Various preliminary data on its medico-social consequences","volume":"45","author":"Navarro","year":"1992","journal-title":"Phlebologie"},{"key":"ref_28","unstructured":"Laing, W. (1992). Chronic Venous Diseases of the Leg, Office of Health Economics."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1742-481X.2010.00660.x","article-title":"Cost-of-illness of chronic leg ulcers in Germany","volume":"7","author":"Purwins","year":"2010","journal-title":"Int. Wound J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1258\/phleb.2010.010s09","article-title":"Societal costs of chronic venous disease in CEAP C4, C5, C6 disease","volume":"25","author":"Rabe","year":"2010","journal-title":"Phlebology"},{"key":"ref_31","unstructured":"Gloviczki, P., and Yao, J. (2001). The physiology and hemodynamics of the normal venous circulation. Handbook of Venous Disorders, Arnold Publisher. [2nd ed.]."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.avsg.2007.03.011","article-title":"Molecular mechanisms in chronic venous insufficiency","volume":"21","author":"Bergan","year":"2007","journal-title":"Ann. Vasc. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13221-014-0024-5","article-title":"Cellular and molecular basis of Venous insufficiency","volume":"6","author":"Pocock","year":"2014","journal-title":"Vasc. Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.avsg.2017.06.131","article-title":"The Role of Endothelial Dysfunction and Inflammation in Chronic Venous Disease","volume":"46","author":"Cardoso","year":"2018","journal-title":"Ann. Vasc. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejvs.2003.10.002","article-title":"Relationship of plasma vascular endothelial growth factor to CEAP clinical stage and symptoms in patients with chronic venous disease","volume":"27","author":"Howlader","year":"2004","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0741-5214(98)70141-7","article-title":"Increased plasma vascular endothelial growth factor among patients with chronic venous disease","volume":"28","author":"Shoab","year":"1998","journal-title":"J. Vasc. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"473765","DOI":"10.1155\/2014\/473765","article-title":"Modulation of circulating cytokine-chemokine profile in patients affected by chronic venous insufficiency undergoing surgical hemodynamic correction","volume":"2014","author":"Tisato","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jss.2008.07.032","article-title":"Evaluation of aFGF\/bFGF and FGF signaling pathway in the wall of varicose veins","volume":"155","author":"Kowalewski","year":"2009","journal-title":"J. Surg. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.ATV.18.5.677","article-title":"Laminar shear stress: Mechanisms by which endothelial cells transduce an atheroprotective force","volume":"18","author":"Traub","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jvs.2009.06.048","article-title":"In vitro differences between smooth muscle cells derived from varicose veins and normal veins","volume":"50","author":"Xiao","year":"2009","journal-title":"J. Vasc. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/path.819","article-title":"Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study","volume":"193","author":"Couvelard","year":"2001","journal-title":"J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1073\/pnas.94.10.5338","article-title":"The leukocyte response to fluid stress","volume":"94","author":"Moazzam","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13152","DOI":"10.1073\/pnas.2336130100","article-title":"Regulation of CD18 expression on neutrophils in response to fluid shear stress","volume":"100","author":"Fukuda","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1749-6632.2001.tb03932.x","article-title":"Endothelial atheroprotective and anti-inflammatory mechanisms","volume":"947","author":"Berk","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"31128","DOI":"10.1074\/jbc.M300703200","article-title":"Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response","volume":"278","author":"Sorescu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/joim.12465","article-title":"The glycocalyx and its significance in human medicine","volume":"280","author":"Tarbell","year":"2016","journal-title":"J. Int. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/01.ATV.0000085630.24353.3D","article-title":"Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface","volume":"23","author":"Constantinescu","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"H1282","DOI":"10.1152\/ajpheart.00117.2002","article-title":"Role of glycocalyx in leukocyte-endothelial cell adhesion","volume":"283","author":"Mulivor","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejvs.2015.04.031","article-title":"Do blood constituents in varicose veins differ from the systemic blood constituents?","volume":"50","author":"Poredos","year":"2015","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejvs.2009.07.021","article-title":"Varicose veins show enhanced chemokine expression","volume":"38","author":"Aceves","year":"2009","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Tisato, V., Zauli, G., Voltan, R., Gianesini, S., di Iasio, M.G., Volpi, I., Fiorentini, G., Zamboni, P., and Secchiero, P. (2012). Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039543"},{"key":"ref_52","first-page":"311","article-title":"Haemoconcentration and accumulation of white cells in the feet during venous stasis","volume":"5","author":"Moyses","year":"1987","journal-title":"Int. J. Microcirc. Clin. Exp."},{"key":"ref_53","first-page":"771","article-title":"White cell and platelet trapping in patients with chronic venous insufficiency","volume":"41","author":"Thomas","year":"1988","journal-title":"Phlebologie"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0741-5214(93)90109-Y","article-title":"Leukocytes: Their role in the etiopathogenesis of skin damage in venous disease","volume":"17","author":"Wilkinson","year":"1993","journal-title":"J. Vasc. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1358863X9700200306","article-title":"The microcirculation in venous hypertension","volume":"2","year":"1997","journal-title":"Vasc. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/bjs.1800680502","article-title":"The relationship between the number of capillaries in the skin of the venous ulcer-bearing area of the lower leg and the fall in foot vein pressure during exercise","volume":"68","author":"Burnand","year":"1981","journal-title":"Br. J. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1523-1747.1998.00369.x","article-title":"Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: Implications for venous ulcer formation","volume":"111","author":"Herouy","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1046\/j.1365-2133.2002.05025.x","article-title":"Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers","volume":"147","author":"Norgauer","year":"2002","journal-title":"Br. J. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1067\/mva.2000.102724","article-title":"Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: A pilot study","volume":"31","author":"Shoab","year":"2000","journal-title":"J. Vasc. Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0741-5214(99)70054-6","article-title":"Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-beta1 gene expression and protein production","volume":"30","author":"Pappas","year":"1999","journal-title":"J. Vasc. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/archderm.1988.01670090032006","article-title":"Overload of iron in the skin of patients with varicose ulcers. Possible contributing role of iron accumulation in progression of the disease","volume":"124","author":"Ackerman","year":"1988","journal-title":"Arch. Dermatol."},{"key":"ref_62","first-page":"CD003229","article-title":"Phlebotonics for venous insufficiency","volume":"4","author":"Vernooij","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1570161052773870","article-title":"Micronized purified flavonoid fraction (MPFF): A review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency","volume":"3","author":"Katsenis","year":"2005","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0268355517692221","article-title":"Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF)","volume":"32","author":"Bush","year":"2017","journal-title":"Phlebology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.23736\/S0392-9590.18.03975-5","article-title":"Efficacy of micronized purified flavonoid fraction Daflon\u00ae on improving individual symptoms, signs and quality of life in patients with chronic venous disease: A systematic review and meta-analysis of randomized double-blind placebo-controlled trials","volume":"37","author":"Kakkos","year":"2018","journal-title":"Int. Angiol."},{"key":"ref_66","first-page":"312","article-title":"Comparative effect of tropolone and diosmin on venous COMT and sympathetic activity in rat","volume":"283","author":"Boudet","year":"1986","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1476-5381.1994.tb14838.x","article-title":"Diosmin-induced increase in sensitivity to Ca2+ of the smooth muscle contractile apparatus in the rat isolated femoral vein","volume":"111","author":"Savineau","year":"1994","journal-title":"Br. J. Pharmacol."},{"key":"ref_68","first-page":"8","article-title":"The human saphenous vein in pharmacology: Effect of a new micronized flavonoid fraction (Daflon 500 mg) on norepinephrine induced contraction","volume":"14","author":"Juteau","year":"1995","journal-title":"Int. Angiol."},{"key":"ref_69","first-page":"41","article-title":"Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg","volume":"7","author":"Barbe","year":"1992","journal-title":"Phlebology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/000331979704800108","article-title":"Venous elasticity after treatment with Daflon 500 mg","volume":"48","author":"Ibegbuna","year":"1997","journal-title":"Angiology"},{"key":"ref_71","first-page":"H2204","article-title":"Capillary perfusion during ischemia-reperfusion in subcutaneous connective tissue and skin muscle","volume":"267","author":"Friesenecker","year":"1994","journal-title":"Am. J. Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000178206","article-title":"Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: In vivo observations in the hamster skin fold","volume":"14","author":"Friesenecker","year":"1994","journal-title":"Int. J. Microcirc. Clin. Exp."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000179261","article-title":"Postischemic leukocyte\/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: Cellular mechanisms and effect of Daflon 500 mg","volume":"17","author":"Korthuis","year":"1997","journal-title":"Int. J. Microcirc. Clin. Exp."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1549-8719.2000.tb00741.x","article-title":"The inflammatory reaction during venous hypertension in the rat","volume":"7","author":"Takase","year":"2000","journal-title":"Microcirculation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejvs.2007.08.011","article-title":"Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg","volume":"35","author":"Pascarella","year":"2008","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejvs.2004.05.012","article-title":"Venous hypertension, inflammation and valve remodeling","volume":"28","author":"Takase","year":"2004","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ejvs.2018.02.009","article-title":"Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension","volume":"55","author":"Cyrino","year":"2018","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.23736\/S0392-9590.17.03868-8","article-title":"Benefits of micronized purified flavonoid fraction as adjuvant therapy on inflammatory response after sclerotherapy","volume":"37","author":"Bogachev","year":"2018","journal-title":"Int. Angiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2174\/1570161113666150827124714","article-title":"Effect of Micronized Purified Flavonoid Fraction Therapy on Endothelin-1 and TNF-alpha Levels in Relation to Antioxidant Enzyme Balance in the Peripheral Blood of Women with Varicose Veins","volume":"13","author":"Pietrzycka","year":"2015","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_80","first-page":"286","article-title":"Superoxide radical concentration and superoxide dismutase (SOD) enzyme activity in varicose veins","volume":"8","author":"Wali","year":"2002","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/ejvs.1998.0751","article-title":"Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous diseasea prospective study","volume":"17","author":"Shoab","year":"1999","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1053\/ejvs.1999.0890","article-title":"Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction\u2014A pilot study","volume":"18","author":"Shoab","year":"1999","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_83","first-page":"39","article-title":"Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg","volume":"7","author":"Laurent","year":"1988","journal-title":"Int. Angiol."},{"key":"ref_84","first-page":"37","article-title":"Quantification of edema using the volometer technique; therapeutic application of Daflon 500 mg in chronic venous insufficiency","volume":"7","author":"Blume","year":"1992","journal-title":"Phlebology"},{"key":"ref_85","first-page":"310","article-title":"Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema","volume":"31","author":"Allaert","year":"2012","journal-title":"Int. Angiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.23736\/S0392-9590.16.03708-1","article-title":"Orthostatic-loading-induced transient venous refluxes (day orthostatic loading test), and remedial effect of micronized purified flavonoid fraction in patients with telangiectasia and reticular vein","volume":"36","author":"Tsukanov","year":"2017","journal-title":"Int. Angiol."},{"key":"ref_87","first-page":"144","article-title":"Diagnosis and treatment of situational great saphenous vein reflux in daily medical practice","volume":"24","author":"Tsukanov","year":"2017","journal-title":"Phlebolymphology"},{"key":"ref_88","first-page":"35","article-title":"Study of capillary filtration by double labelling I131-albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mg","volume":"7","author":"Behar","year":"1988","journal-title":"Int. Angiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000179095","article-title":"Laser Doppler and transcutaneous oximetry: Modern investigations to assess drug efficacy in chronic venous insufficiency","volume":"15","author":"Belcaro","year":"1995","journal-title":"Int. J. Microcirc. Clin. Exp."},{"key":"ref_90","first-page":"69","article-title":"A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility","volume":"12","author":"Galley","year":"1993","journal-title":"Int. Angiol."},{"key":"ref_91","first-page":"81","article-title":"Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation","volume":"27","author":"Paysant","year":"2008","journal-title":"Int. Angiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0268355514564414","article-title":"Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon\u00ae 500 mg) on microvascular damage elicited by sclerotherapy","volume":"31","author":"Cyrino","year":"2016","journal-title":"Phlebology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/000331979704800113","article-title":"Efficacy of Daflon 500 mg in venous leg ulcer healing: A double-blind, randomized, controlled versus placebo trial in 107 patients","volume":"48","author":"Guilhou","year":"1997","journal-title":"Angiology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/026835559901400405","article-title":"The Beneficial Augmentative Effect of Micronised Purified Flavonoid Fraction (MPFF) on the Healing of Leg Ulcers: An Open, Multicentre, Controlled, Randomised Study","volume":"14","author":"Chodynicka","year":"1999","journal-title":"Phlebology"},{"key":"ref_95","first-page":"24","article-title":"Efficacy of a 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency","volume":"22","author":"Roztocil","year":"2003","journal-title":"Int. Angiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0011-393X(05)80444-8","article-title":"Therapeutic value of hidrosmin in the treatment of venous disorders of the lower limbs","volume":"52","author":"Fermoso","year":"1992","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_97","first-page":"376","article-title":"Insuffisance veineuse et Daflon 500 mg [Venous insufficiency and Daflon 500 mg]","volume":"9","author":"Planchon","year":"2016","journal-title":"Art\u00e8res Veines"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/026835559400900206","article-title":"Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: A double-blind, placebo-controlled study","volume":"9","author":"Gilly","year":"1994","journal-title":"Phlebology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1177\/000331970205300301","article-title":"Chronic venous insufficiency: Worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids","volume":"53","author":"Jantet","year":"2002","journal-title":"Angiology"},{"key":"ref_100","first-page":"428","article-title":"Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: From a prospective randomized trial","volume":"34","author":"Rabe","year":"2015","journal-title":"Int. Angiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1186\/ar2372","article-title":"Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis","volume":"10","author":"Kauss","year":"2008","journal-title":"Arthritis Res. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3831\/KPI.2017.20.003","article-title":"Treatment with Rutin\u2014A Therapeutic Strategy for Neutrophil-Mediated Inflammatory and Autoimmune Diseases\u2014Anti-inflammatory Effects of Rutin on Neutrophils","volume":"20","author":"Nikfarjam","year":"2017","journal-title":"J. Pharmacopunct."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/026835559601100210","article-title":"A double-blind clinical trial of hydroxyethylrutosides in the treatment of the symptoms and signs of chronic venous insufficiency","volume":"11","author":"Cloarec","year":"1996","journal-title":"Phlebology"},{"key":"ref_104","first-page":"309","article-title":"Treatment of venous insufficiency. A double-blind trial with Phlebodril","volume":"61","author":"Kriner","year":"1985","journal-title":"Z. Allg."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000213574","article-title":"Hydroxyethylrutosides in elderly patients with chronic venous insufficiency: Its efficacy and tolerability","volume":"40","author":"MacLennan","year":"1994","journal-title":"Gerontology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1024\/0301-1526.31.3.185","article-title":"The efficacy and safety of a coumarin-\/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: A double blind placebo-controlled randomised study","volume":"31","author":"Vanscheidt","year":"2002","journal-title":"VASA"},{"key":"ref_107","first-page":"76","article-title":"Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients","volume":"9","author":"Balmer","year":"1980","journal-title":"VASA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1055\/s-2008-1070921","article-title":"Effect of calcium dobesilate on permeation of plasma proteins in diabetic patients","volume":"105","author":"Beyer","year":"1980","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_109","first-page":"580","article-title":"Platelet aggregation inhibition with calcium dobesilate","volume":"33","author":"Heidrich","year":"1983","journal-title":"Arzneim. Forsch."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000265364","article-title":"Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy","volume":"17","author":"Benarroch","year":"1985","journal-title":"Ophthalmic Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/sj.bjp.0701512","article-title":"Dobesilate enhances endothelial nitric oxide synthase-activity in macro- and microvascular endothelial cells","volume":"122","author":"Suschek","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF01963593","article-title":"Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant human myometrium in vitro Calcium dobesilate and its effects on hemorheology and microcirculation","volume":"40","author":"Falkay","year":"1984","journal-title":"Experientia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/000331978803901001","article-title":"A double-blind trial of calcium dobesilate in chronic venous insufficiency","volume":"39","year":"1988","journal-title":"Angiology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1258\/phleb.2010.010051","article-title":"Calcium dobesilate in patients suffering from chronic venous insufficiency: A double-blind, placebo-controlled, clinical trial","volume":"26","author":"Rabe","year":"2011","journal-title":"Phlebology"},{"key":"ref_115","first-page":"105","article-title":"Doxium 500 in chronic venous insufficiency: A double-blind placebo controlled multicentre study","volume":"9","author":"Widmer","year":"1990","journal-title":"Int. Angiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejvs.2007.08.012","article-title":"A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease","volume":"35","author":"Moreno","year":"2008","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/DDDT.S6762","article-title":"Development and use of sulodexide in vascular diseases: Implications for treatment","volume":"8","author":"Coccheri","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1007\/s00125-010-1910-x","article-title":"Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus","volume":"53","author":"Broekhuizen","year":"2010","journal-title":"Diabetologia"},{"key":"ref_119","first-page":"236","article-title":"Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease","volume":"33","author":"Mannello","year":"2014","journal-title":"Int. Angiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/089686080302300615","article-title":"Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients","volume":"23","author":"Fracasso","year":"2003","journal-title":"Perit. Dial. Int."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.trsl.2008.12.007","article-title":"Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity","volume":"153","author":"Ciszewicz","year":"2009","journal-title":"Transl. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/ndt\/gfr370","article-title":"Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion","volume":"27","author":"Pletinck","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1159\/000113011","article-title":"Anti-inflammatory effect of sulodexide during acute peritonitis in rats","volume":"25","author":"Karon","year":"2007","journal-title":"Blood Purif."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/1570161111666131126144025","article-title":"Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: Role of glycosaminoglycans in inflammatory pathways of chronic venous disease","volume":"12","author":"Mannello","year":"2014","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.bbadis.2016.07.018","article-title":"Chronic venous disease\u2014Part I: Inflammatory biomarkers in wound healing","volume":"1862","author":"Ligi","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2174\/1570161111311030010","article-title":"Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: Possible pharmacological role against collagen degradation in vascular chronic diseases","volume":"11","author":"Mannello","year":"2013","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.bbadis.2016.07.011","article-title":"Chronic venous disease\u2014Part II: Proteolytic biomarkers in wound healing","volume":"1862","author":"Ligi","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_128","first-page":"589","article-title":"Sulodexide suppresses inflammation in patients with chronic venous insufficiency","volume":"34","author":"Urbanek","year":"2015","journal-title":"Int. Angiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1185\/03007999309111538","article-title":"Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency","volume":"13","author":"Saviano","year":"1993","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s12325-016-0359-9","article-title":"Sulodexide in Patients with Chronic Venous Disease of the Lower Limbs: Clinical Efficacy and Impact on Quality of Life","volume":"33","author":"Elleuch","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1055\/s-0037-1613116","article-title":"Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers","volume":"87","author":"Coccheri","year":"2002","journal-title":"Thromb. Haemost."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/000331979905001102","article-title":"Treatment of venous leg ulcers with sulodexide","volume":"50","author":"Scondotto","year":"1999","journal-title":"Angiology"},{"key":"ref_133","first-page":"82","article-title":"Sulodexide and phlebotonics in the treatment of venous ulcer","volume":"36","year":"2017","journal-title":"Int. Angiol."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Wu, B., Lu, J., Yang, M., and Xu, T. (2016). Sulodexide for treating venous leg ulcers. Cochrane Database Syst. Rev., CD010694.","DOI":"10.1002\/14651858.CD010694.pub2"},{"key":"ref_135","first-page":"236","article-title":"Venous hemodynamic changes in lower limb venous disease: The UIP consensus according to scientific evidence","volume":"35","author":"Lee","year":"2016","journal-title":"Int. Angiol."},{"key":"ref_136","first-page":"87","article-title":"Management of chronic venous disorders of the lower limbs\u2014guidelines according to scientific evidence","volume":"33","author":"Nicolaides","year":"2014","journal-title":"Int. Angiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/j.jvs.2011.01.079","article-title":"The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum","volume":"53","author":"Gloviczki","year":"2011","journal-title":"J. Vasc. Surg."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:07:23Z","timestamp":1760195243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":137,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["ijms19061669"],"URL":"https:\/\/doi.org\/10.3390\/ijms19061669","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]}}}